Furthermore, IFN-mediated mechanisms of resistance have been also reported for standard of care treatment in breast cancer, such as aromatase inhibitors (AIs), that have been shown able to induce the overexpression of ISGs in cancer cells [107]. This evidence concerns the gene IFNA1 and cancer.